Christiana Care CCOP was originally funded by NCI in 1987 and has continued since that time. It was organized to facilitate participation in CALGB, NSABP, CCG, RTOG and MD Anderson clinical trials by community physicians in the region. Christiana Care Health Services (CCHS) (formerly the Medical Center of Delaware) has a long standing relationship with CALGB, NSABP and CCG and has participated in patient accrual since 1966. RTOG and MD Anderson were added as research bases over the last funding cycle. We have an extensive catchment area which encompasses all of Delaware, and portions of New Jersey, northeastern Maryland, and southeastern Pennsylvania (Montgomery, Delaware and Chester counties). This represents a population base in excess of 2 million people with extensive protocol entry potential. Over the last three years this population has increased with the addition of the Cooper Hospital/University Medical Center group. At that time the NCI approached our principal investigator, Dr. Irving Berkowitz to request that the New Jersey group be incorporated into the Delaware CCOP, almost doubling our catchment area. This relationship has continued to grow and has resulted in increased accrual. CCOP investigators, project coordinators and data managers continue to participate in Core Committees of CALGB, NSABP, CCG, RTOG and MD Anderson research bases. The overall impact of this grant will be to assure continuation and stimulate expansion of CCOP activities, including treatment and cancer control research, at CCHS and its affiliates throughout our catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045418-14
Application #
6172463
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (J4))
Project Start
1987-08-05
Project End
2002-05-31
Budget Start
2000-08-03
Budget End
2001-05-31
Support Year
14
Fiscal Year
2000
Total Cost
$579,785
Indirect Cost
Name
Christiana Care Health Services, Inc.
Department
Type
DUNS #
City
Newark
State
DE
Country
United States
Zip Code
19713
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Williams, Michael E; Hong, Fangxin; Gascoyne, Randy D et al. (2016) Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 173:867-75
Morrison, Vicki A; Jung, Sin-Ho; Johnson, Jeffrey et al. (2015) Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma 56:958-64
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21

Showing the most recent 10 out of 100 publications